Ratings by Mizuho (Salim Syed)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/23/2026 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 6/16/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 6/16/2026 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 6/15/2026 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 6/15/2026 | Assembly Biosciences | ASMB | Maintain | Outperform (N/A) |
|
Details | ||
| 6/8/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 6/2/2026 | Enliven Therapeutics | ELVN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/26/2026 | Century Therapeutics | IPSC | New Coverage | Outperform (N/A) |
2.26 (2.41) |
6.64% | Details | |
| 5/14/2026 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 4/30/2026 | Sutro Biopharma | STRO | New Coverage | Outperform (N/A) |
35.39 (29.19) |
-17.52% | Details | |
| 4/28/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 4/20/2026 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/20/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2026 | Syndax Pharmaceuticals | SNDX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2026 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2026 | Maze Therapeutics | MAZE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/24/2026 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/24/2026 | Enliven Therapeutics | ELVN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/24/2026 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/18/2026 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/18/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/10/2026 | Maze Therapeutics | MAZE | New Coverage | Outperform (N/A) |
44.83 (26.41) |
-41.09% | Details | |
| 2/19/2026 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/11/2026 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 2/11/2026 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/7/2026 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2025 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2025 | Atara Biotherapeutics | ATRA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2025 | Assembly Biosciences | ASMB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2025 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2025 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 8/18/2025 | Atara Biotherapeutics | ATRA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/18/2025 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/11/2025 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 6/18/2025 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 6/10/2025 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/30/2025 | Enliven Therapeutics | ELVN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/29/2025 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 5/19/2025 | Unity Biotechnology Inc | UBX | Downgrade | Neutral (Outperform) |
0.82 (0.20) |
-75.61% | Details | |
| 5/16/2025 | Unity Biotechnology Inc | UBX | Downgrade | Neutral (Outperform) |
0.76 (0.20) |
-73.68% | Details | |
| 5/7/2025 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2025 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/5/2025 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2025 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2025 | Unity Biotechnology Inc | UBX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/10/2025 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2025 | Vaxcyte | PCVX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2024 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2024 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2024 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2024 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 10/18/2024 | Cytokinetics | CYTK | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/1/2024 | Enliven Therapeutics | ELVN | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/25/2024 | WAVE Life Sciences | WVE | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/24/2024 | Assembly Biosciences | ASMB | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/23/2024 | Enliven Therapeutics | ELVN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/13/2024 | Gilead Sciences | GILD | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/10/2024 | Vaxcyte | PCVX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/4/2024 | Cytokinetics | CYTK | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/3/2024 | Vaxcyte | PCVX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/3/2024 | BridgeBio Pharma | BBIO | Maintain | Outperform (Outperform) |
|
Details | ||
| 8/19/2024 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/19/2024 | Enliven Therapeutics | ELVN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/16/2024 | Atara Biotherapeutics | ATRA | Upgrade | Outperform (Neutral) |
6.83 (11.16) |
63.4% | Details | |
| 8/6/2024 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 6/17/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2024 | Amgen | AMGN | Maintain | (N/A) |
|
Details | ||
| 4/9/2024 | Enliven Therapeutics | ELVN | New Coverage | Outperform (N/A) |
18.30 (48.60) |
165.57% | Details | |
| 4/5/2024 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/22/2024 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2024 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2024 | Vaxcyte | PCVX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2024 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2024 | CRISPR Therapeutics | CRSP | Maintain | Outperform (N/A) |
|
Details | ||
| 3/5/2024 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/5/2024 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/22/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/22/2024 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 1/22/2024 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 1/19/2024 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 12/27/2023 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 12/7/2023 | Vaxcyte | PCVX | New Coverage | Outperform (N/A) |
53.71 (51.96) |
-3.26% | Details | |
| 11/16/2023 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2023 | Atara Biotherapeutics | ATRA | Downgrade | Neutral () |
1.33 (11.16) |
739.1% | Details | |
| 9/27/2023 | CRISPR Therapeutics | CRSP | New Coverage | Outperform (N/A) |
45.86 (53.99) |
17.73% | Details | |
| 8/14/2023 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2023 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2023 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2023 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 7/18/2023 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 6/7/2023 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/24/2023 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2023 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/28/2023 | Unity Biotechnology Inc | UBX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/14/2023 | Coherus Biosciences | CHRS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2023 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2023 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/16/2022 | Unity Biotechnology Inc | UBX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/16/2022 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/16/2022 | Coherus Biosciences | CHRS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/16/2022 | Assembly Biosciences | ASMB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2022 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/1/2022 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 9/28/2022 | Biogen | BIIB | Upgrade | Outperform (Neutral) |
195.75 (197.19) |
0.74% | Details | |
| 9/12/2022 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 9/12/2022 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/23/2022 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 8/16/2022 | Unity Biotechnology Inc | UBX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/16/2022 | Coherus Biosciences | CHRS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/16/2022 | Atara Biotherapeutics | ATRA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/20/2022 | Coherus Biosciences | CHRS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/16/2022 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2022 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2022 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/18/2022 | Gilead Sciences | GILD | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/7/2022 | Gilead Sciences | GILD | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/1/2022 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 1/14/2022 | Cytokinetics | CYTK | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/13/2022 | Gilead Sciences | GILD | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/12/2022 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 12/27/2021 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/1/2021 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/22/2021 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 11/19/2021 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2021 | Unity Biotechnology Inc | UBX | Upgrade | Outperform (Neutral) |
2.36 (0.76) |
-67.8% | Details | |
| 10/26/2021 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 8/13/2021 | WAVE Life Sciences | WVE | Maintain | Neutral (N/A) |
|
Details | ||
| 8/13/2021 | Assembly Biosciences | ASMB | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2021 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2021 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2021 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/4/2021 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/2/2021 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 7/27/2021 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/11/2021 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2021 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/19/2021 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/7/2020 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/4/2020 | Assembly Biosciences | ASMB | Maintain | Outperform (N/A) |
|
Details | ||
| 12/2/2020 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 11/23/2020 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/23/2020 | Atara Biotherapeutics | ATRA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 11/2/2020 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/27/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 8/18/2020 | Unity Biotechnology Inc | UBX | Downgrade | Neutral (Outperform) |
12.43 (0.20) |
-98.39% | Details | |
| 8/4/2020 | Nkarta Inc. | NKTX | New Coverage | Outperform (N/A) |
26.58 (3.03) |
-88.6% | Details | |
| 7/22/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 7/22/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 6/18/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 6/5/2020 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 6/5/2020 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 6/2/2020 | Assembly Biosciences | ASMB | Maintain | Outperform (N/A) |
|
Details | ||
| 6/1/2020 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2020 | Cytokinetics | CYTK | New Coverage | Outperform (N/A) |
14.49 (80.01) |
452.17% | Details | |
| 2/19/2020 | BridgeBio Pharma | BBIO | New Coverage | Outperform (N/A) |
34.65 (68.63) |
98.07% | Details | |
| 2/14/2020 | Bristol-Myers Squibb Co. CVR | BMY-R | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2019 | Bristol-Myers Squibb Co. CVR | BMY-R | Maintain | Outperform (N/A) |
|
Details | ||
| 11/25/2019 | Bristol-Myers Squibb Co. CVR | BMY-R | New Coverage | Outperform (N/A) |
0.00 () |
0% | Details | |
| 11/21/2019 | Neon Therapeutics | NTGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/29/2019 | Amgen | AMGN | Maintain | Neutral (Neutral) |
|
Details | ||
| 10/16/2019 | Assembly Biosciences | ASMB | New Coverage | Outperform (N/A) |
9.01 (26.80) |
197.45% | Details | |
| 9/11/2019 | Atara Biotherapeutics | ATRA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/9/2019 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/23/2019 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/19/2019 | Celgene | CELG | Downgrade | Neutral (Outperform) |
94.74 (108.24) |
14.25% | Details | |
| 6/5/2019 | Atara Biotherapeutics | ATRA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/21/2019 | Biogen | BIIB | Downgrade | Neutral (Outperform) |
320.59 (197.19) |
-38.49% | Details | |
| 2/27/2019 | Atara Biotherapeutics | ATRA | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/23/2019 | Atara Biotherapeutics | ATRA | New Coverage | Outperform (N/A) |
37.25 (11.16) |
-70.04% | Details | |
| 1/16/2019 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2018 | Celgene | CELG | Maintain | Outperform (N/A) |
|
Details | ||
| 9/7/2018 | Unity Biotechnology Inc | UBX | New Coverage | Outperform (N/A) |
17.75 (0.20) |
-98.87% | Details |
